BACE2 inhibition impairs oncogenic programs and extracellular vesicle-mediated tumor proliferation in Ewing sarcoma
Ontology highlight
ABSTRACT: Ewing sarcoma (EWS) is an aggressive pediatric malignancy with poor outcomes in relapsed or metastatic disease and limited targeted therapeutic options. To identify disease-relevant vulnerabilities, we employed a propagatable patient-derived xenograft (pPDX) platform in which serial in vivo passaging enriches for highly aggressive tumors with increased tumor-initiating capacity (TIC). These models preserved the molecular hallmarks of EWS and revealed a transcriptional program associated with tumor aggressiveness. Within this context, β-secretase 2 (BACE2) emerged as constitutively overexpressed and was validated at the protein level across a large primary EWS cohort. Proteomic profiling following BACE2 inhibition demonstrated dose-dependent alterations in pathways governing cell cycle progression and vesicle transport. Genetic and pharmacologic targeting of BACE2 impaired EWS cell proliferation and viability in vitro and abolished tumor-initiating activity in vivo. Mechanistically, BACE2 inhibition disrupted the production and function of EWS-derived extracellular vesicles (EVs), reducing their capacity to promote tumor cell proliferation, activate fibroblasts, and impair endothelial barrier integrity. Importantly, direct intratumoral administration of a BACE2 inhibitor robustly suppressed growth of established EWS PDX tumors. Collectively, these findings identify BACE2 as a previously unrecognized therapeutic vulnerability in Ewing sarcoma and establish BACE2 as a regulator of both tumor-intrinsic oncogenic programs and extracellular vesicle-mediated intercellular communication.
ORGANISM(S): Homo sapiens
PROVIDER: GSE256506 | GEO | 2026/09/08
REPOSITORIES: GEO
ACCESS DATA